This study analysed data obtained from a phase III clinical trial involving 218 post-menopausal women with vaginal atrophy who received daily intravaginal DHEA (0.25%, 0.5% or 1.0%) for a 12-week period. One of the main findings was that the 0.5% DHEA daily intravaginal dose was found to have a ‘statistically significant’ to ‘highly significant’ effect on all parameters of vaginal atrophy. It was also found to not significantly affect the serum levels of estrogens, further emphasising its clinical effectiveness.
